Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Ministerio de EconomÃa y Competitividad, Spain | OTHER_GOV |
| Centro de Estudios, Investigación y Medicina del Deporte | OTHER_GOV |
| Fundación Instituto de Investigación Sanitaria de Navarra | OTHER |
Not provided
Not provided
Not provided
Not provided
Dysfunction of adipose tissue in obesity, inflammation and aging: mechanisms and effects of physical exercise and omega-3 fatty acids.
Obesity is associated with the development of metabolic diseases including type 2 diabetes and immune disorders. Obesity also leads to reduced lifespan and accelerated cellular processes similar to those of aging. On the other hand, aging is accompanied by the accumulation of visceral fat and the metabolic complications associated to obesity. Both obesity and aging have been identified as chronic, low-grade inflammation disorders. The inflammation in aging has been considered as a risk factor for the development of most of age-related diseases, and therefore for morbidity and mortality in the elderly. However, the specific mechanisms leading to inflammation in aging remain largely unknown.
Resolution of inflammation is an active process which involves production of several series of specialized pro-resolving lipid mediators such lipoxins, resolvin, protectins and maresin. The hypothesis of this trial is that the chronic inflammation associated to obesity and aging could be the result of an impaired production of these specialized pro-resolutive lipid mediators, mainly in adipose tissue. On the other hand, the investigators also propose that altered transcriptional pattern might be responsible for the development of the inflammation associated with the pathophysiology of obesity and aging. Therefore the first general aim of the current project will be to characterize the mechanisms involved in the unresolved chronic inflammation that arises during obesity and aging.
Because n-3 PUFAs (polyunsaturated fatty acids) serve as substrates for the synthesis of specialized pro-resolving lipid mediators and are important transcriptional regulators, the investigators propose that dietary supplementation with n-3 PUFAs, alone or in combination with regular physical exercise could promote the resolution of local and systemic inflammation and the subsequent metabolic disorders associated to obesity and aging. A trial in overweight/obese postmenopausal women will be carried out to characterize the potential beneficial effects of regular administration of a DHA-rich dietary supplement and/or a progressive resistance training (PRT) program on weight and fat mass loss, insulin sensitivity, inflammatory markers and gene/miRNA/lipidomic/metabolomic profile in serum and/or adipose tissue. Moreover, changes in gut microbiota will be also addressed.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Control | Placebo Comparator | Dietary advice for a healthy diet supplemented with placebo (olive oil). |
|
| Omega-3 | Experimental | Dietary advice for a healthy diet supplemented with DHA-rich dietary supplement (providing 1.650 mg/day of DHA). |
|
| Resistance Training | Experimental | Dietary advice for a healthy diet supplemented with placebo (olive oil) and moderate resistance training program. |
|
| Omega-3 + Resistance Training | Experimental | Dietary advice for a healthy diet supplemented with a DHA-rich dietary supplement (providing 1.650 mg/day of DHA) and moderate resistance training program. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Omega-3 (DHA-rich dietary supplement) | Dietary Supplement | Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks. |
| Measure | Description | Time Frame |
|---|---|---|
| Fat mass reduction | Evaluation of body fat mass changes induced by the different interventions, analyzed by Dual X-ray Absorptiometry (DXA). | Week 0 (baseline) |
| Fat mass reduction | Evaluation of body fat mass changes induced by the different interventions, analyzed by Dual X-ray Absorptiometry (DXA). | Week 16 (end of intervention) |
| Measure | Description | Time Frame |
|---|---|---|
| Evolution of fat mass reduction | Evaluation of body fat mass changes induced by the different interventions analyzed by bioimpedance. | Week 0 (baseline) |
| Evolution of fat mass reduction | Evaluation of body fat mass changes induced by the different interventions analyzed by bioimpedance. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| MarÃa J Moreno-Aliaga, PhD | University of Navarra | Principal Investigator |
| Silvia Lorente-Cebrián, PhD | University of Navarra | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Nutrition, Food Science and Physiology. Centre for Nutrition Research. | Pamplona | Navarre | 31008 | Spain |
| PubMed Identifier | Type | Citation | Retractions |
|---|---|---|---|
| 28188173 | Background | Martinez-Fernandez L, Gonzalez-Muniesa P, Laiglesia LM, Sainz N, Prieto-Hontoria PL, Escote X, Odriozola L, Corrales FJ, Arbones-Mainar JM, Martinez JA, Moreno-Aliaga MJ. Maresin 1 improves insulin sensitivity and attenuates adipose tissue inflammation in ob/ob and diet-induced obese mice. FASEB J. 2017 May;31(5):2135-2145. doi: 10.1096/fj.201600859R. Epub 2017 Feb 10. | |
| 28096235 |
| Label | URL |
|---|---|
| Centre for Nutrition Research. University of Navarra | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| D009765 | Obesity |
| D007249 | Inflammation |
| D007333 | Insulin Resistance |
| D009043 | Motor Activity |
| ID | Term |
|---|---|
| D050177 | Overweight |
| D044343 | Overnutrition |
| D009748 | Nutrition Disorders |
| D009750 | Nutritional and Metabolic Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| D004281 | Docosahexaenoic Acids |
| D000069463 | Olive Oil |
| D055070 | Resistance Training |
| ID | Term |
|---|---|
| D015525 | Fatty Acids, Omega-3 |
| D004042 | Dietary Fats, Unsaturated |
| D004041 | Dietary Fats |
| D005223 | Fats |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Placebo (olive oil) | Dietary Supplement | Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks. |
|
| Resistance training | Other | Double-blind randomized placebo-controlled intervention with DHA-rich dietary supplement with or without resistance training program for 16 weeks. |
|
| Week 2 |
| Evolution of fat mass reduction | Evaluation of body fat mass changes induced by the different interventions analyzed by bioimpedance. | Week 4 |
| Evolution of fat mass reduction | Evaluation of body fat mass changes induced by the different interventions analyzed by bioimpedance. | Week 6 |
| Evolution of fat mass reduction | Evaluation of body fat mass changes induced by the different interventions analyzed by bioimpedance. | Week 8 |
| Evolution of fat mass reduction | Evaluation of body fat mass changes induced by the different interventions analyzed by bioimpedance. | Week 10 |
| Evolution of fat mass reduction | Evaluation of body fat mass changes induced by the different interventions analyzed by bioimpedance. | Week 12 |
| Evolution of fat mass reduction | Evaluation of body fat mass changes induced by the different interventions analyzed by bioimpedance. | Week 14 |
| Evolution of fat mass reduction | Evaluation of body fat mass changes induced by the different interventions analyzed by bioimpedance. | Week 16 (end of intervention) |
| Weight loss | Changes in body weight will be measured by a body weight scale to the nearest 0.1 kg | Week 0 (baseline) |
| Weight loss | Changes in body weight will be measured by a body weight scale to the nearest 0.1 kg | Week 2 |
| Weight loss | Changes in body weight will be measured by a body weight scale to the nearest 0.1 kg | Week 4 |
| Weight loss | Changes in body weight will be measured by a body weight scale to the nearest 0.1 kg | Week 6 |
| Weight loss | Changes in body weight will be measured by a body weight scale to the nearest 0.1 kg | Week 8 |
| Weight loss | Changes in body weight will be measured by a body weight scale to the nearest 0.1 kg | Week 10 |
| Weight loss | Changes in body weight will be measured by a body weight scale to the nearest 0.1 kg | Week 12 |
| Weight loss | Changes in body weight will be measured by a body weight scale to the nearest 0.1 kg | Week 14 |
| Weight loss | Changes in body weight will be measured by a body weight scale to the nearest 0.1 kg | Week 16 (end of intervention) |
| Evolution of body composition | Evaluation of fat-free mass changes will be analyzed by bioimpedance. | Week 0 (baseline) |
| Evolution of body composition | Evaluation of fat-free mass changes will be analyzed by bioimpedance. | Week 2 |
| Evolution of body composition | Evaluation of fat-free mass changes will be analyzed by bioimpedance. | Week 4 |
| Evolution of body composition | Evaluation of fat-free mass changes will be analyzed by bioimpedance. | Week 6 |
| Evolution of body composition | Evaluation of fat-free mass changes will be analyzed by bioimpedance. | Week 8 |
| Evolution of body composition | Evaluation of fat-free mass changes will be analyzed by bioimpedance. | Week 10 |
| Evolution of body composition | Evaluation of fat-free mass changes will be analyzed by bioimpedance. | Week 12 |
| Evolution of body composition | Evaluation of fat-free mass changes will be analyzed by bioimpedance. | Week 14 |
| Evolution of body composition | Evaluation of fat-free mass changes will be analyzed by bioimpedance. | Week 16 (end of intervention) |
| Hip circumference | Hip circumference will be measured with a measuring tape. | Week 0 (baseline) |
| Hip circumference | Hip circumference will be measured with a measuring tape. | Week 8 |
| Hip circumference | Hip circumference will be measured with a measuring tape. | Week 16 (end of intervention) |
| Neck circumference | Neck circumference will be measured with a measuring tape. | Week 0 (baseline) |
| Neck circumference | Neck circumference will be measured with a measuring tape. | Week 8 |
| Neck circumference | Neck circumference will be measured with a measuring tape. | Week 16 (end of intervention) |
| Waist circumference | Waist circumference will be measured with a measuring tape. | Week 0 (baseline) |
| Waist circumference | Waist circumference will be measured with a measuring tape. | Week 8 |
| Waist circumference | Waist circumference will be measured with a measuring tape. | Week 16 (end of intervention) |
| Abdomen circumference | Abdomen circumference will be measured with a measuring tape. | Week 0 (baseline) |
| Abdomen circumference | Abdomen circumference will be measured with a measuring tape. | Week 8 |
| Abdomen circumference | Abdomen circumference will be measured with a measuring tape. | Week 16 (end of intervention) |
| Arm circumference | Arm circumference will be measured with a measuring tape. | Week 0 (baseline) |
| Arm circumference | Arm circumference will be measured with a measuring tape. | Week 8 |
| Arm circumference | Arm circumference will be measured with a measuring tape. | Week 16 (end of intervention) |
| Midthigh circumference | Midthigh circumference will be measured with a measuring tape. | Week 0 (baseline) |
| Midthigh circumference | Midthigh circumference will be measured with a measuring tape. | Week 8 |
| Midthigh circumference | Midthigh circumference will be measured with a measuring tape. | Week 16 (end of intervention) |
| Midcalf circumference | Midcalf circumference will be measured with a measuring tape. | Week 0 (baseline) |
| Midcalf circumference | Midcalf circumference will be measured with a measuring tape. | Week 8 |
| Midcalf circumference | Midcalf circumference will be measured with a measuring tape. | Week 16 (end of intervention) |
| Triceps skinfold | Triceps skinfold will be measured with a caliper. | Week 0 (baseline) |
| Triceps skinfold | Triceps skinfold will be measured with a caliper. | Week 8 |
| Triceps skinfold | Triceps skinfold will be measured with a caliper. | Week 16 (end of intervention) |
| Thigh skinfold | Thigh skinfold will be measured with a caliper. | Week 0 (baseline) |
| Thigh skinfold | Thigh skinfold will be measured with a caliper. | Week 8 |
| Thigh skinfold | Thigh skinfold will be measured with a caliper. | Week 16 (end of intervention) |
| Medial calf skinfold | Medial calf skinfold will be measured with a caliper. | Week 0 (baseline) |
| Medial calf skinfold | Medial calf skinfold will be measured with a caliper. | Week 8 |
| Medial calf skinfold | Medial calf skinfold will be measured with a caliper. | Week 16 (end of intervention) |
| Blood pressure | Systolic and diastolic blood pressure will be measured with a tensiometer. | Week 0 (baseline) |
| Blood pressure | Systolic and diastolic blood pressure will be measured with a tensiometer. | Week 8 |
| Blood pressure | Systolic and diastolic blood pressure will be measured with a tensiometer. | Week 16 (end of intervention) |
| Serum glucose | Fasting serum glucose will be measured after overnight fast. | Week 0 (baseline) |
| Serum glucose | Fasting serum glucose will be measured after overnight fast. | Week 16 (end of intervention) |
| Serum insulin | Fasting serum insulin will be measured after overnight fast. | Week 0 (baseline) |
| Serum insulin | Fasting serum insulin will be measured after overnight fast. | Week 16 (end of intervention) |
| Oral Glucose Tolerance Test | Oral Glucose Tolerance Test will be carried out after overnight fast. | Week 0 (baseline) |
| Oral Glucose Tolerance Test | Oral Glucose Tolerance Test will be carried out after overnight fast. | Week 16 (end of intervention) |
| Lipid metabolism biomarkers | Serum free fatty acids, triglycerides, total cholesterol, LDL-cholesterol and HDL-cholesterol concentrations will be measured after an overnight fast. | Week 0 (baseline) |
| Lipid metabolism biomarkers | Serum free fatty acids, triglycerides, total cholesterol, LDL-cholesterol and HDL-cholesterol concentrations will be measured after an overnight fast. | Week 16 (end of intervention) |
| Ketone bodies | Ketone bodies concentrations will be measured after an overnight fast. | Week 0 (baseline) |
| Ketone bodies | Ketone bodies concentrations will be measured after an overnight fast. | Week 16 (end of intervention) |
| Thyroid function (body metabolism) | TSH (thyroid-stimulating hormone), T3 and T4 hormones will be evaluated with ELISA kits | Week 0 (baseline) |
| Thyroid function (body metabolism) | TSH (thyroid-stimulating hormone), T3 and T4 hormones will be evaluated with ELISA kits | Week 16 (end of intervention) |
| Cardiovascular risk biomarkers | PAI-1 (plasminogen activator inhibitor-1), ADMA (asymmetric dimethylarginine) and VEGF (vascular endothelial growth factor) will be measured in plasma using ELISA kits | Week 0 (baseline) |
| Cardiovascular risk biomarkers | PAI-1 (plasminogen activator inhibitor-1), ADMA (asymmetric dimethylarginine) and VEGF (vascular endothelial growth factor) will be measured in plasma using ELISA kits | Week 16 (end of intervention) |
| Inflammation biomarkers | TNF-α (tumour necrosis factor-alpha), IL-6 (interleukin 6), C-reactive protein, serum A-amyloid, leptin, adiponectin, chemerin will be measured by ELISA kits | Week 0 (baseline) |
| Inflammation biomarkers | TNF-α (tumour necrosis factor-alpha), IL-6 (interleukin 6), C-reactive protein, serum A-amyloid, leptin, adiponectin, chemerin will be measured in plasma by ELISA kits | Week 16 (end of intervention) |
| Satiety and eating behavior traits | Satiety will be also estimated by using a VAS (visual analogue scale) questionnaire and eating behavior traits will be also evaluated with validated questionnaires | Week 0 (baseline) |
| Satiety and eating behavior traits | Satiety will be also estimated by using a VAS (visual analogue scale) questionnaire and eating behavior traits will be also evaluated with validated questionnaires | Week 16 (end of intervention) |
| Plasma adipokines and myo-kines | CT-1, irisin, FGF21 (fibroblast growth factor 21) and meteorin-like will be measured using ELISA kits | Week 0 (baseline) |
| Plasma adipokines and myo-kines | CT-1, irisin, FGF21 (fibroblast growth factor 21) and meteorin-like will be measured using ELISA kits | Week 16 (end of intervention) |
| Plasma lipids and bioactive lipid mediators | Lipidomic profile will be measured using targeted metabolomic-lipidomics by HPLC-MS (high pressure liquid chromatography-mass spectrometry). | Week 0 (baseline) |
| Plasma lipids and bioactive lipid mediators | Lipidomic profile will be measured using targeted metabolomic-lipidomics by HPLC-MS (high pressure liquid chromatography-mass spectrometry). | Week 16 (end of intervention) |
| Adipose tissue gene profiling | A biopsy (2 g) of subcutaneous abdominal periumbilical area adipose tissue will be obtained by liposuction under local anesthesia. RNA expression will be measured by RNA-seq or GeneChip Human Gene 2.1 ST Array (Affymetrix). | Week 0 (baseline) |
| Adipose tissue gene profiling | A biopsy (2 g) of subcutaneous abdominal periumbilical area adipose tissue will be obtained by liposuction under local anesthesia. RNA expression will be measured by RNA-seq or GeneChip Human Gene 2.1 ST Array (Affymetrix). | Week 16 (end of intervention) |
| Adipose tissue miRNA profiling | MiRNA expression will be measured by RNA-seq or GeneChip miRNA 4.0 Array (Affymetrix) in subcutaneous abdominal adipose tissue biopsies. | Week 0 (baseline) |
| Adipose tissue miRNA profiling | MiRNA expression will be measured by RNA-seq or GeneChip miRNA 4.0 Array (Affymetrix) in subcutaneous abdominal adipose tissue biopsies. | Week 16 (end of intervention) |
| Bioactive lipid mediators involved in inflammation in adipose tissue | Lipidomic profile will be measured using targeted metabolomic-lipidomics by HPLC-MS | Week 0 (baseline) |
| Bioactive lipid mediators involved in inflammation in adipose tissue | Lipidomic profile will be measured using targeted metabolomic-lipidomics by HPLC-MS | Week 16 (end of intervention) |
| Determination of telomeres length | Telomeres length will be measured in genomic DNA extracted from human peripheral blood and adipose tissue samples with a real-time quantitative PCR (polymerase chain reaction) approach. | Week 0 (baseline) |
| Determination of telomeres length | Telomeres length will be measured in genomic DNA extracted from human peripheral blood and adipose tissue samples with a real-time quantitative PCR (polymerase chain reaction) approach. | Week 16 (end of intervention) |
| Characterization of gut microbiota | Feces will collected and gut microbiota profiling will be carried out by high-throughput 16S (Svedberg units) rDNA (ribosomal deoxyribonucleic acid) amplicon sequencing approach. | Week 0 (baseline) |
| Characterization of gut microbiota | Feces will collected and gut microbiota profiling will be carried out by high-throughput 16S (Svedberg units) rDNA (ribosomal deoxyribonucleic acid) amplicon sequencing approach. | Week 16 (end of intervention) |
| Urine metabolomic profile | Urine will be collected and urinary metabolomic profile will be also evaluated by a HPLC-MS approach. | Week 0 (baseline) |
| Urine metabolomic profile | Urine will be collected and urinary metabolomic profile will be also evaluated by a HPLC-MS approach. | Week 16 (end of intervention) |
| Background |
| Lopez-Yoldi M, Stanhope KL, Garaulet M, Chen XG, Marcos-Gomez B, Carrasco-Benso MP, Santa Maria EM, Escote X, Lee V, Nunez MV, Medici V, Martinez-Anso E, Sainz N, Huerta AE, Laiglesia LM, Prieto J, Martinez JA, Bustos M, Havel PJ, Moreno-Aliaga MJ. Role of cardiotrophin-1 in the regulation of metabolic circadian rhythms and adipose core clock genes in mice and characterization of 24-h circulating CT-1 profiles in normal-weight and overweight/obese subjects. FASEB J. 2017 Apr;31(4):1639-1649. doi: 10.1096/fj.201600396RR. Epub 2017 Jan 17. |
| 27637001 | Background | Laiglesia LM, Lorente-Cebrian S, Prieto-Hontoria PL, Fernandez-Galilea M, Ribeiro SM, Sainz N, Martinez JA, Moreno-Aliaga MJ. Eicosapentaenoic acid promotes mitochondrial biogenesis and beige-like features in subcutaneous adipocytes from overweight subjects. J Nutr Biochem. 2016 Nov;37:76-82. doi: 10.1016/j.jnutbio.2016.07.019. Epub 2016 Aug 26. |
| 27507611 | Background | Huerta AE, Prieto-Hontoria PL, Fernandez-Galilea M, Escote X, Martinez JA, Moreno-Aliaga MJ. Effects of dietary supplementation with EPA and/or alpha-lipoic acid on adipose tissue transcriptomic profile of healthy overweight/obese women following a hypocaloric diet. Biofactors. 2017 Jan 2;43(1):117-131. doi: 10.1002/biof.1317. Epub 2016 Aug 10. |
| 26962183 | Background | Huerta AE, Prieto-Hontoria PL, Sainz N, Martinez JA, Moreno-Aliaga MJ. Supplementation with alpha-Lipoic Acid Alone or in Combination with Eicosapentaenoic Acid Modulates the Inflammatory Status of Healthy Overweight or Obese Women Consuming an Energy-Restricted Diet. J Nutr. 2015 Apr 1;146(4):889S-896S. doi: 10.3945/jn.115.224105. |
| 26760097 | Background | Milagro FI, Moreno-Aliaga MJ, Martinez JA. FTO Obesity Variant and Adipocyte Browning in Humans. N Engl J Med. 2016 Jan 14;374(2):190-1. doi: 10.1056/NEJMc1513316. No abstract available. |
| 26721419 | Background | Prieto-Hontoria PL, Perez-Matute P, Fernandez-Galilea M, Lopez-Yoldi M, Sinal CJ, Martinez JA, Moreno-Aliaga MJ. Effects of alpha-lipoic acid on chemerin secretion in 3T3-L1 and human adipocytes. Biochim Biophys Acta. 2016 Mar;1861(3):260-8. doi: 10.1016/j.bbalip.2015.12.011. Epub 2015 Dec 22. |
| 26219838 | Background | Martinez-Fernandez L, Laiglesia LM, Huerta AE, Martinez JA, Moreno-Aliaga MJ. Omega-3 fatty acids and adipose tissue function in obesity and metabolic syndrome. Prostaglandins Other Lipid Mediat. 2015 Sep;121(Pt A):24-41. doi: 10.1016/j.prostaglandins.2015.07.003. Epub 2015 Jul 26. |
| 26213922 | Background | Mansego ML, Milagro FI, Zulet MA, Moreno-Aliaga MJ, Martinez JA. Differential DNA Methylation in Relation to Age and Health Risks of Obesity. Int J Mol Sci. 2015 Jul 24;16(8):16816-32. doi: 10.3390/ijms160816816. |
| 25820474 | Background | Huerta AE, Prieto-Hontoria PL, Fernandez-Galilea M, Sainz N, Cuervo M, Martinez JA, Moreno-Aliaga MJ. Circulating irisin and glucose metabolism in overweight/obese women: effects of alpha-lipoic acid and eicosapentaenoic acid. J Physiol Biochem. 2015 Sep;71(3):547-58. doi: 10.1007/s13105-015-0400-5. Epub 2015 Mar 28. |
| 25752887 | Background | Lorente-Cebrian S, Costa AG, Navas-Carretero S, Zabala M, Laiglesia LM, Martinez JA, Moreno-Aliaga MJ. An update on the role of omega-3 fatty acids on inflammatory and degenerative diseases. J Physiol Biochem. 2015 Jun;71(2):341-9. doi: 10.1007/s13105-015-0395-y. Epub 2015 Mar 11. |
| 25594166 | Background | Huerta AE, Navas-Carretero S, Prieto-Hontoria PL, Martinez JA, Moreno-Aliaga MJ. Effects of alpha-lipoic acid and eicosapentaenoic acid in overweight and obese women during weight loss. Obesity (Silver Spring). 2015 Feb;23(2):313-21. doi: 10.1002/oby.20966. Epub 2014 Dec 31. |
| 23975165 | Background | Gonzalez-Muniesa P, Marrades MP, Martinez JA, Moreno-Aliaga MJ. Differential proinflammatory and oxidative stress response and vulnerability to metabolic syndrome in habitual high-fat young male consumers putatively predisposed by their genetic background. Int J Mol Sci. 2013 Aug 22;14(9):17238-55. doi: 10.3390/ijms140917238. |
| 23794360 | Background | Lorente-Cebrian S, Costa AG, Navas-Carretero S, Zabala M, Martinez JA, Moreno-Aliaga MJ. Role of omega-3 fatty acids in obesity, metabolic syndrome, and cardiovascular diseases: a review of the evidence. J Physiol Biochem. 2013 Sep;69(3):633-51. doi: 10.1007/s13105-013-0265-4. Epub 2013 Jun 22. |
| 21497077 | Background | Lorente-Cebrian S, Bustos M, Marti A, Fernandez-Galilea M, Martinez JA, Moreno-Aliaga MJ. Eicosapentaenoic acid inhibits tumour necrosis factor-alpha-induced lipolysis in murine cultured adipocytes. J Nutr Biochem. 2012 Mar;23(3):218-27. doi: 10.1016/j.jnutbio.2010.11.018. Epub 2011 Apr 14. |
| 20975297 | Background | Marrades MP, Gonzalez-Muniesa P, Martinez JA, Moreno-Aliaga MJ. A dysregulation in CES1, APOE and other lipid metabolism-related genes is associated to cardiovascular risk factors linked to obesity. Obes Facts. 2010 Oct;3(5):312-8. doi: 10.1159/000321451. Epub 2010 Oct 15. |
| 20882379 | Background | Marrades MP, Gonzalez-Muniesa P, Arteta D, Martinez JA, Moreno-Aliaga MJ. Orchestrated downregulation of genes involved in oxidative metabolic pathways in obese vs. lean high-fat young male consumers. J Physiol Biochem. 2011 Mar;67(1):15-26. doi: 10.1007/s13105-010-0044-4. Epub 2010 Sep 30. |
| 20540825 | Background | Moreno-Aliaga MJ, Lorente-Cebrian S, Martinez JA. Regulation of adipokine secretion by n-3 fatty acids. Proc Nutr Soc. 2010 Aug;69(3):324-32. doi: 10.1017/S0029665110001801. Epub 2010 Jun 14. |
| 20352620 | Background | Lorente-Cebrian S, Bustos M, Marti A, Martinez JA, Moreno-Aliaga MJ. Eicosapentaenoic acid up-regulates apelin secretion and gene expression in 3T3-L1 adipocytes. Mol Nutr Food Res. 2010 May;54 Suppl 1:S104-11. doi: 10.1002/mnfr.200900522. |
| 19296827 | Background | Lorente-Cebrian S, Bustos M, Marti A, Martinez JA, Moreno-Aliaga MJ. Eicosapentaenoic acid stimulates AMP-activated protein kinase and increases visfatin secretion in cultured murine adipocytes. Clin Sci (Lond). 2009 Aug 14;117(6):243-9. doi: 10.1042/CS20090020. |
| 18829285 | Background | Perez-Echarri N, Perez-Matute P, Marcos-Gomez B, Marti A, Martinez JA, Moreno-Aliaga MJ. Down-regulation in muscle and liver lipogenic genes: EPA ethyl ester treatment in lean and overweight (high-fat-fed) rats. J Nutr Biochem. 2009 Sep;20(9):705-14. doi: 10.1016/j.jnutbio.2008.06.013. Epub 2008 Sep 30. |
| Department of Nutrition, Food Science and Physiology. University of Navarra | View source |
| D001835 |
| Body Weight |
| D012816 | Signs and Symptoms |
| D013568 | Pathological Conditions, Signs and Symptoms |
| D010335 | Pathologic Processes |
| D006946 | Hyperinsulinism |
| D044882 | Glucose Metabolism Disorders |
| D008659 | Metabolic Diseases |
| D001519 | Behavior |
| D008055 |
| Lipids |
| D005231 | Fatty Acids, Unsaturated |
| D005227 | Fatty Acids |
| D005395 | Fish Oils |
| D009821 | Oils |
| D005224 | Fats, Unsaturated |
| D010938 | Plant Oils |
| D005502 | Food |
| D000066888 | Diet, Food, and Nutrition |
| D010829 | Physiological Phenomena |
| D019602 | Food and Beverages |
| D005081 | Exercise Therapy |
| D012046 | Rehabilitation |
| D000359 | Aftercare |
| D003266 | Continuity of Patient Care |
| D005791 | Patient Care |
| D013812 | Therapeutics |
| D026741 | Physical Therapy Modalities |
| D064797 | Physical Conditioning, Human |
| D015444 | Exercise |
| D009043 | Motor Activity |
| D009068 | Movement |
| D009142 | Musculoskeletal Physiological Phenomena |
| D055687 | Musculoskeletal and Neural Physiological Phenomena |